search
Back to results

Study Using Negative Pressure to Reduce Apnea (SUPRA)

Primary Purpose

Sleep Apnea, Obstructive, Apnea, Sleep

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
aerSleep II
Sponsored by
Sommetrics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea, Obstructive focused on measuring sleep apnea, OSA, obstructive sleep apnea, CPAP failure, apnea

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18 years old
  2. Body mass index ≤42 kg/m2
  3. Prior documented diagnosis of OSA by means of a polysomnography (PSG) test or home sleep test (HST)
  4. Documented evidence from a screening HST following consent to demonstrate:

    1. AHI 15 - 50/hour
    2. >80% of the apneas and hypopneas are obstructive
  5. Previous treatment attempt with CPAP resulting in failure to treat or discontinuation due to intolerance, subject choice, or struggle to use CPAP
  6. Have not used CPAP or oral appliances within 1 week of the screening home sleep test and agree not to use CPAP or oral appliances throughout the study duration
  7. Access to and ability to use a smart device such as a smartphone or tablet
  8. Able to speak, read, and write English
  9. In the opinion of the investigator, the subject will be able to understand and comply with all study procedures.

Exclusion Criteria:

  1. Known sleep disorder other than OSA, such as narcolepsy, restless leg syndrome, idiopathic hypersomnolence or chronic insomnia
  2. Craniofacial abnormalities that may be contributing to OSA
  3. Previous surgery, injury, or radiation to the neck which, in the Investigator's judgment, could interfere with collar fit or comfort
  4. Excessive hair or beard in the area of the neck where the collar will be placed, and/or unwillingness to shave that area for the duration of this study
  5. Inflammatory skin condition, such as acne or eczema in the area where the collar will be affixed to the skin, which, in the Investigator's judgment, could interfere with collar fit or comfort
  6. Known silicone allergy
  7. Night shift work because of irregular sleep-wake cycles
  8. Excessive alcohol intake, defined as that leading to interference with work, home life, or the ability to optimally perform normal everyday duties and tasks
  9. Use of illicit drugs currently or within the past 5 years
  10. Serious pulmonary disease (e.g., cor pulmonale, CO2 retention, or poorly controlled asthma)
  11. Use of home oxygen or baseline oxygen saturation <94%
  12. Cancer that has been in remission for less than one year
  13. Psychiatric illness that, in the opinion of the Investigator, is not reasonably well-controlled with treatment
  14. Serious cardiac disease (e.g., congestive heart failure, unstable coronary artery disease, or poorly controlled rhythm disturbance)
  15. Prior carotid endarterectomy, prior percutaneous coronary angiography (including any placement of carotid stents), or known stenosis of either internal carotid artery > 70% from prior carotid imaging (e.g., carotid duplex ultrasound, angiography, computed tomography angiography, or magnetic resonance angiography)
  16. Previous surgery for peripheral arterial disease
  17. Presence of possible or definite carotid artery disease, defined as any of the following:

    1. history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) with uncertain etiology that is compatible with carotid artery disease
    2. diminished carotid pulse on screening physical examination*
    3. > 70% stenosis in either extra-cranial internal carotid artery as determined by duplex ultrasound* (only performed on those who do not exhibit 17 a. or b.)
  18. Tonsil size 3 or 4 (Appendix C)*
  19. Currently pregnant* or planning to become pregnant during participation in this study
  20. Unable to obtain adequate collar fit*
  21. Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, or bias the results
  22. The investigator believes that the subject's participation may not be in his or her best interest

Sites / Locations

  • University of Arizona
  • Preferred Research Partners
  • Infinitive Bioresearch
  • BetterNight
  • Delta Waves
  • Baptist Hospital
  • Clayton Sleep Institute
  • The MetroHealth System
  • Cleveland Clinic Foundation
  • The Ohio State University
  • Thomas Jefferson University
  • UPMC
  • Bogan Sleep Consultants
  • BioSerenity
  • Sleep Therapy & Research Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

aerSleep II

Arm Description

Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP

Outcomes

Primary Outcome Measures

Sustained response to aerSleep II therapy at 24 weeks
The primary effectiveness endpoint is to demonstrate that a majority of adult subjects who are initial responders to aerSleep II therapy experience a change of at least 50% of their baseline AHI with an AHI rate less than 20 per hour at the final home sleep test at 24 weeks.
Adverse Device Effects
The primary safety endpoint is to characterize the adverse device effects experienced throughout the study.

Secondary Outcome Measures

ODI change
Demonstrate a change in Oxygen Desaturation Index (ODI) at HST #4 compared to baseline HST for initial responders
AHI change from baseline for all subjects that acclimate to the aerSleep II device
Determine the proportion of subjects that acclimate to the device that exhibit a change in AHI after 24 weeks of home use with the aerSleep II device
Change in sleep disturbance from baseline as measured by Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance questionnaire
Determine the change in sleep disturbance at the end of the study compared to baseline using the validated PROMIS Short Form Sleep Disturbance 8b questionnaire
Change in sleep impairment from baseline as measured by PROMIS Sleep Sleep-Related Impairment questionnaire
Determine the change in sleep impairment at the end of the study from baseline as measured by the validated PROMIS Short Form Sleep-Related Impairment 8a questionnaire
Change in sleep from baseline as measured by Patient Global Impression Scale questionnaire
Determine any change in sleep at the end of the study from baseline as measured by the Patient Global Impression Scale questionnaire

Full Information

First Posted
April 22, 2021
Last Updated
July 17, 2023
Sponsor
Sommetrics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04861038
Brief Title
Study Using Negative Pressure to Reduce Apnea
Acronym
SUPRA
Official Title
Study Using Negative Pressure to Reduce Apnea (SUPRA)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
November 29, 2021 (Actual)
Primary Completion Date
September 2024 (Anticipated)
Study Completion Date
September 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sommetrics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to determine the safety and effectiveness of the aerSleep® II device for treatment of moderate to severe Obstructive Sleep Apnea (OSA) over 24 weeks of home use in spontaneously breathing adult subjects who are intolerant of Continuous Positive Airway Pressure (CPAP) therapy.
Detailed Description
This is a multi-center, single-arm, prospective, observational intervention study to determine the safety and effectiveness of the aerSleep II System. Up to 900 subjects will be enrolled at up to 30 study sites in the United States and outside the United States to ensure that approximately 79 subjects who are termed initial responders can be evaluated after 24 weeks of home use with the aerSleep II device. As part of screening and prior to intervention, home sleep testing will be performed to establish baseline apnea-hypopnea index (AHI). Subjects meeting study criteria will wear the aerSleep II device at home. After a 1-week period of acclimation, subjects will have a second HST (HST #2). Initial responders with a ≥50% reduction in AHI from baseline with an AHI <20/hour will be continued on home treatment. Non-responders will be discontinued from the study. After 12 weeks, subjects will have an interim home sleep study. After 24 weeks of home use, subjects will have HST #4 to determine the primary effectiveness endpoint.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Obstructive, Apnea, Sleep
Keywords
sleep apnea, OSA, obstructive sleep apnea, CPAP failure, apnea

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
900 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
aerSleep II
Arm Type
Experimental
Arm Description
Use of aerSleep II device to provide continuous external negative pressure to treat moderate to severe OSA in spontaneously breathing subjects who are intolerant of CPAP
Intervention Type
Device
Intervention Name(s)
aerSleep II
Intervention Description
Continuous negative external pressure (cNEP) system that maintains an open airway by applying negative pressure to the anterior neck via a soft silicone collar
Primary Outcome Measure Information:
Title
Sustained response to aerSleep II therapy at 24 weeks
Description
The primary effectiveness endpoint is to demonstrate that a majority of adult subjects who are initial responders to aerSleep II therapy experience a change of at least 50% of their baseline AHI with an AHI rate less than 20 per hour at the final home sleep test at 24 weeks.
Time Frame
24 weeks
Title
Adverse Device Effects
Description
The primary safety endpoint is to characterize the adverse device effects experienced throughout the study.
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
ODI change
Description
Demonstrate a change in Oxygen Desaturation Index (ODI) at HST #4 compared to baseline HST for initial responders
Time Frame
24 weeks
Title
AHI change from baseline for all subjects that acclimate to the aerSleep II device
Description
Determine the proportion of subjects that acclimate to the device that exhibit a change in AHI after 24 weeks of home use with the aerSleep II device
Time Frame
24 weeks
Title
Change in sleep disturbance from baseline as measured by Patient Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance questionnaire
Description
Determine the change in sleep disturbance at the end of the study compared to baseline using the validated PROMIS Short Form Sleep Disturbance 8b questionnaire
Time Frame
24 weeks
Title
Change in sleep impairment from baseline as measured by PROMIS Sleep Sleep-Related Impairment questionnaire
Description
Determine the change in sleep impairment at the end of the study from baseline as measured by the validated PROMIS Short Form Sleep-Related Impairment 8a questionnaire
Time Frame
24 weeks
Title
Change in sleep from baseline as measured by Patient Global Impression Scale questionnaire
Description
Determine any change in sleep at the end of the study from baseline as measured by the Patient Global Impression Scale questionnaire
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old Body mass index ≤42 kg/m2 Prior documented diagnosis of OSA by means of a polysomnography (PSG) test or home sleep test (HST) Documented evidence from a screening HST following consent to demonstrate: AHI 15 - 50/hour >80% of the apneas and hypopneas are obstructive Previous treatment attempt with CPAP resulting in failure to treat or discontinuation due to intolerance, subject choice, or struggle to use CPAP Have not used CPAP or oral appliances within 1 week of the screening home sleep test and agree not to use CPAP or oral appliances throughout the study duration Access to and ability to use a smart device such as a smartphone or tablet Able to speak, read, and write English In the opinion of the investigator, the subject will be able to understand and comply with all study procedures. Exclusion Criteria: Known sleep disorder other than OSA, such as narcolepsy, restless leg syndrome, idiopathic hypersomnolence or chronic insomnia Craniofacial abnormalities that may be contributing to OSA Previous surgery, injury, or radiation to the neck which, in the Investigator's judgment, could interfere with collar fit or comfort Excessive hair or beard in the area of the neck where the collar will be placed, and/or unwillingness to shave that area for the duration of this study Inflammatory skin condition, such as acne or eczema in the area where the collar will be affixed to the skin, which, in the Investigator's judgment, could interfere with collar fit or comfort Known silicone allergy Night shift work because of irregular sleep-wake cycles Excessive alcohol intake, defined as that leading to interference with work, home life, or the ability to optimally perform normal everyday duties and tasks Use of illicit drugs currently or within the past 5 years Serious pulmonary disease (e.g., cor pulmonale, CO2 retention, or poorly controlled asthma) Use of home oxygen or baseline oxygen saturation <94% Cancer that has been in remission for less than one year Psychiatric illness that, in the opinion of the Investigator, is not reasonably well-controlled with treatment Serious cardiac disease (e.g., congestive heart failure, unstable coronary artery disease, or poorly controlled rhythm disturbance) Prior carotid endarterectomy, prior percutaneous coronary angiography (including any placement of carotid stents), or known stenosis of either internal carotid artery > 70% from prior carotid imaging (e.g., carotid duplex ultrasound, angiography, computed tomography angiography, or magnetic resonance angiography) Previous surgery for peripheral arterial disease Presence of possible or definite carotid artery disease, defined as any of the following: history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) with uncertain etiology that is compatible with carotid artery disease diminished carotid pulse on screening physical examination* > 70% stenosis in either extra-cranial internal carotid artery as determined by duplex ultrasound* (only performed on those who do not exhibit 17 a. or b.) Tonsil size 3 or 4 (Appendix C)* Currently pregnant* or planning to become pregnant during participation in this study Unable to obtain adequate collar fit* Any condition or circumstance that, in the opinion of the investigator, may preclude study completion, interfere with accurate data collection, or bias the results The investigator believes that the subject's participation may not be in his or her best interest
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kingman P. Strohl, M.D.
Organizational Affiliation
Case Western Reserve University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Arizona
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Facility Name
Preferred Research Partners
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72211
Country
United States
Facility Name
Infinitive Bioresearch
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Facility Name
BetterNight
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
Delta Waves
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80918
Country
United States
Facility Name
Baptist Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33176
Country
United States
Facility Name
Clayton Sleep Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63123
Country
United States
Facility Name
The MetroHealth System
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States
Facility Name
Cleveland Clinic Foundation
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Thomas Jefferson University
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
UPMC
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Bogan Sleep Consultants
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29201
Country
United States
Facility Name
BioSerenity
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29212
Country
United States
Facility Name
Sleep Therapy & Research Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study Using Negative Pressure to Reduce Apnea

We'll reach out to this number within 24 hrs